Invokana Lawsuit Plaintiffs Concerned By Recent FDA Bone Fracture Warnings Linked To Drug

March 29, 2016 – – TheProductLawyers.com reports on another potential side effect warning from the U.S. Food and Drug Administration (FDA) which involves two similar drugs: Invokana and Invokamet. The drugs are both SGLT2 class inhibitors used to treat type-2 diabetes patients, and the FDA has recently indicated that they have received many adverse event reports surrounding the drugs linking them to weakened bone density and bone fracture risks among patients taking them.

The FDA stated, “Fractures were observed as early as 12 weeks after treatment initiation, and were more likely to be low trauma (e.g., arising after falls from no more than standing height) and affect the upper extremities.” They also reviewed a study which oversaw 714 elderly patients. Among these patients, results showed that those who were using Invokana had developed increased bone loss in their spine and hip areas. Warnings discussing side effects involving patient’s bones have been on the drug’s warning label since its release to market.

Invokana was released to market following its approval by the FDA in 2013. The drug was the first of a group of similar SGLT2 class inhibitor drugs to be released and, out of the group, reportedly currently has the most adverse events linked to it. The drug works by helping to maintain blood sugar (glucose) levels in type-2 diabetes patients. To accomplish this task, it prevents the kidneys from reabsorbing extra glucose, and instead rids the body of this glucose (sugar) through urination. To do this, however, Invokana must heavily rely on the kidneys and can allegedly stress or damage them as well.

The Endocrinologic and Metabolic Drugs Advisory Committee has also discussed bone density and bone fracture warnings surrounding these SGLT2 class inhibitor drugs. The committee noted bone density loss which was seen during clinical trials on the drugs. Reportedly, some patients taking the drugs have claimed to have broken bones after suffering just minor falls–such as tripping over something while on a walk.

The attorneys of Banville Law are dedicated to keeping all important drug information available to the general public. To better accomplish this, they sponsor the resource website TheProductLawyers.com, and are also working to assist patients who have taken SGLT2 class inhibitor drugs and who believe that their use of the drugs has caused them to suffer from adverse events. The attorneys of Banville Law believe that it is incredibly important to ensure that these patients will be given an opportunity to fully investigate their legal rights in the matter. To assist those desiring to explore these rights, they are currently offering free legal consultations for qualified parties. Affected patients may be entitled to substantial compensation.

To request additional Invokana lawsuit information, or to ask questions, contact the attorneys of Banville Law by calling 877-671-6480.

###

Contact TheProductLawyers.com:

Banville Law
877-671-6480
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60008949